About this medicine

Ziprasidone is a second-generation antipsychotic. A current NHS formulary explicitly identifies it as unlicensed in the UK. Scottish local medicines guidance also uses it as an example of an imported unlicensed medicine. That is a different situation from a UK-licensed antipsychotic used outside one of its approved indications.

This article provides meaningful UK context for people encountering Geodon or Zeldox abroad. It does not say that the medicine is forbidden, routinely stocked, recommended for a particular person or funded by every NHS service.

What is this medicine used for?

Foreign Geodon information describes oral treatment of schizophrenia and certain bipolar-I episodes, and short-acting intramuscular treatment of agitation associated with schizophrenia. These are foreign product indications, not UK licensing or a general British rapid-tranquillisation protocol.

Exceptional UK use needs an assessed clinical reason, adequate evidence, informed discussion and a prescriber who accepts monitoring responsibility. The existence of an overseas authorisation is not enough to establish a local treatment pathway.

Which warning signs need help?

Fainting with a racing or irregular heartbeat needs urgent assessment. Fever, marked rigidity, confusion or collapse can signal a serious reaction. Severe rash with blistering or mouth sores, seizure, a prolonged painful erection or suspected overdose also warrants urgent help.

Older adults with dementia have increased mortality risk with antipsychotic treatment. This safety information is not a UK indication and is not labelled an MHRA 'boxed warning'. New or worsening suicidal thoughts also need urgent clinical attention.

How do I take it safely?

Foreign capsules are swallowed whole with food. Their strengths and schedules are not reproduced as UK dosing. The foreign intramuscular product is administered by trained staff and must not be treated as a capsule substitute or self-injection.

For an imported medicine, pharmacy teams must establish the actual product and supply arrangements. Import notification is not equivalent to MHRA approval. No named brand, stocked formulation or dose conversion is certified by this educational record.

What side effects should I know about?

Sleepiness, dizziness, restlessness, digestive symptoms and movement effects can occur. Some people develop changes in weight, glucose, lipids or prolactin-related symptoms. Feeling less sedated than on another medicine does not establish lower overall risk.

Driving and hazardous tasks require attention to alertness, balance and the effect of alcohol. New persistent abnormal movements need clinical review rather than being dismissed as anxiety.

Who needs extra care with this medicine?

The foreign label excludes use in important QT-risk situations, including known QT prolongation, a recent myocardial infarction, uncompensated heart failure and certain interacting medicines. Low potassium or magnesium, liver disease, seizures, diabetes, dehydration and swallowing problems also require attention.

This selected explanation does not replace checking the complete supplied-product label. In particular, a normal-looking pulse or lack of symptoms cannot rule out a relevant cardiac risk.

Can it affect my other medicines?

Other QT-prolonging medicines are a major interaction concern. MAO inhibitors and medicines or supplements affecting serotonin also need careful review; St John's wort and tryptophan are not automatically safe because they can be bought without prescription.

Review the complete medicine list and recent starts or stops. Alcohol may worsen impaired alertness. Do not interpret omission from this short list as evidence that a combination is safe.

What check-ups will I need?

Clinical review considers response, movement effects, weight and metabolic health. Cardiac risk assessment includes relevant history and medicines; electrolyte testing and ECG assessment depend on the circumstances. This article does not impose a universal UK testing schedule derived from a foreign label.

An unlicensed-use plan should state who reviews benefit and adverse effects, how problems are communicated and when continuing treatment will be reconsidered.

What about pregnancy, breastfeeding and age?

Late-pregnancy antipsychotic exposure can cause newborn movement or withdrawal problems. Breastfeeding also needs a specific assessment of exposure and infant effects. Decisions should consider untreated illness as well as the medicine, rather than prompt abrupt self-discontinuation.

Foreign adult indications do not establish UK paediatric authorisation. Older people, particularly those with dementia, need a distinct assessment of cardiovascular, movement, falls and other risks.

What if I miss a dose or want to stop?

Treatment should not be stopped simply because symptoms improve. Discuss stopping or interruption with the prescribing team, and do not double a dose to compensate for a missed one. The actual product instructions and agreed plan take precedence over a general website explanation.

A change in access after moving country should prompt medication reconciliation and coordinated advice, not an unplanned conversion to another antipsychotic.

How does it work?

Ziprasidone blocks dopamine D2 and serotonin 5-HT2 receptors, proteins that receive messages from the chemicals dopamine and serotonin. D2 and 5-HT2 identify particular receiving-site types, and 5-HT is another name for serotonin. Blocking their activation changes how cells respond to those messages and may contribute to treatment benefit.

Laboratory studies also show effects at other receptors and reduced reuptake of serotonin and noradrenaline. Reuptake is the return of a chemical messenger into a nerve cell after release, so reducing it changes how much remains available between cells. The full mechanism of clinical benefit is uncertain, and these laboratory findings do not establish a use for treating depression.

How does it affect my body?

Pharmacodynamics means what a medicine does to the body. Dopamine and serotonin receptor blockade changes signalling in brain circuits. Alpha-1 receptor binding helps explain why blood-pressure effects deserve attention. Receptor actions do not provide a simple ranking of clinical benefit or adverse effects.

Ziprasidone can prolong QT, a measured part of the heart's electrical cycle. In susceptible circumstances this can contribute to dangerous arrhythmias. Cardiac history, other medicines and electrolyte problems matter even when a person has no warning symptoms.

How does my body process it?

Food substantially affects oral absorption. This is a product-administration issue, not a suggestion to adjust the dose according to a meal. The short-acting injection has different absorption from a capsule and is not a long-acting depot.

The liver extensively processes ziprasidone through reduction pathways, including aldehyde oxidase, and oxidative pathways involving CYP3A4. Much clearance is not CYP-mediated. The foreign injection contains a cyclodextrin ingredient cleared by the kidneys, so oral and injected formulations must not be assumed to have identical renal precautions.

How do treatment options differ?

Different antipsychotics vary in receptor effects, cardiac risk, metabolic effects, formulation and evidence. Ziprasidone's food-dependent oral absorption and QT considerations are important distinctions, not a complete ranking of medicines.

No equivalent dose or UK substitution is supplied. A shared antipsychotic class does not make one medicine interchangeable with another or confer authorisation on an imported product.

A closer look at the science

The ziprasidone parent molecule contains carbon, hydrogen, chlorine, nitrogen, oxygen and sulphur. The foreign oral and injectable products use different salt and water-of-crystallisation components. Chemical connectivity is not the same as a receptor-binding pose, a tablet formulation or instructions for preparing an injection.

A shared active molecule therefore does not mean that a capsule and an injection have identical handling, absorption or safety considerations.

How was this medicine developed?

International use and UK access have followed different paths. Current Nottinghamshire formulary information calls ziprasidone unlicensed; Greater Glasgow and Clyde guidance discusses it within unlicensed prescribing rather than as a routine licensed UK medicine.

Local NHS policies do not necessarily describe every pharmacy's stock or every nation's funding arrangements. An imported medicine needs a specific clinical and supply plan; international use alone does not create routine UK access.

Sources and References

  1. Antipsychotic medicines: ziprasidone formulary entry

    Scope: England; Nottinghamshire local formulary.

  2. Off-label and unlicensed prescribing

    Scope: Scotland; Greater Glasgow and Clyde local medicines governance.

  3. Geodon: US prescribing information

    Scope: United States; foreign product context only.

  4. Ziprasidone: patient medicine information

    Scope: United States; general safety education, not UK authorisation.

  5. Prescribing unlicensed medicines

    Scope: United Kingdom.

  6. Understanding unlicensed medicines

    Scope: United Kingdom medicines governance.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top